TY - JOUR
T1 - Active von Willebrand Factor in patients with a bleeding diathesis
AU - van der Vorm, Lisa N.
AU - Huskens, Dana
AU - Florin, Lisa
AU - De Kesel, Pieter
AU - Roest, Mark
AU - de Laat, Bas
AU - Devreese, Katrien M.J.
N1 - Funding Information:
We would like to thank Diëgo Arnoe, Julie De Leenheer, An De Saar, Michael Luypaert and Esha Wauters for their technical support.
Publisher Copyright:
© 2020 The Author(s)
PY - 2020/12/1
Y1 - 2020/12/1
N2 - Introduction: Increased levels of circulating von Willebrand Factor (VWF) in its active, platelet-binding conformation have been implicated in the pathogenesis of several thrombotic conditions as well as bleeding conditions characterized by severe thrombocytopenia. However, it is unclear whether the proportion of activated VWF in the circulation also plays a role in patients with mild to moderate bleeding without thrombocytopenia. Methods: Citrated plasma samples were collected from 145 patients with a bleeding diathesis with unknown cause. Active VWF levels were measured with an in-house developed ELISA assay. In addition, VWF antigen (VWF:Ag), VWF ristocetin cofactor activity (VWF:RCo) and (flow-cytometric) platelet-VWF binding (Plt:VWF) were determined. Results: Active VWF levels were on average mildly, but not significantly, lowered in patients with a bleeding diathesis compared to the reference interval (especially in individuals with non-O blood groups). Active VWF was not significantly different for subjects with (median 107.4%, IQR 18.3) versus without (median 111.1%, IQR 32.3%) an increased bleeding score, nor between subjects with suspected VWD (median 104%, IQR 20.6%) versus other suspected causes of bleeding diathesis (median 111.7%, IQR 33.3%). Conclusion: In this clinically heterogeneous population of patients with a mild bleeding phenotype, quantification of active VWF levels does not have added diagnostic value to VWF:Ag and VWF activity assays in the diagnosis of unexplained bleeding disorders.
AB - Introduction: Increased levels of circulating von Willebrand Factor (VWF) in its active, platelet-binding conformation have been implicated in the pathogenesis of several thrombotic conditions as well as bleeding conditions characterized by severe thrombocytopenia. However, it is unclear whether the proportion of activated VWF in the circulation also plays a role in patients with mild to moderate bleeding without thrombocytopenia. Methods: Citrated plasma samples were collected from 145 patients with a bleeding diathesis with unknown cause. Active VWF levels were measured with an in-house developed ELISA assay. In addition, VWF antigen (VWF:Ag), VWF ristocetin cofactor activity (VWF:RCo) and (flow-cytometric) platelet-VWF binding (Plt:VWF) were determined. Results: Active VWF levels were on average mildly, but not significantly, lowered in patients with a bleeding diathesis compared to the reference interval (especially in individuals with non-O blood groups). Active VWF was not significantly different for subjects with (median 107.4%, IQR 18.3) versus without (median 111.1%, IQR 32.3%) an increased bleeding score, nor between subjects with suspected VWD (median 104%, IQR 20.6%) versus other suspected causes of bleeding diathesis (median 111.7%, IQR 33.3%). Conclusion: In this clinically heterogeneous population of patients with a mild bleeding phenotype, quantification of active VWF levels does not have added diagnostic value to VWF:Ag and VWF activity assays in the diagnosis of unexplained bleeding disorders.
KW - Active von willebrand factor
KW - Bleeding diathesis
KW - Platelets
KW - von willebrand disease
UR - http://www.scopus.com/inward/record.url?scp=85126124153&partnerID=8YFLogxK
U2 - 10.1016/j.tru.2020.100001
DO - 10.1016/j.tru.2020.100001
M3 - Article
SN - 2666-5727
VL - 1
JO - Thrombosis Update
JF - Thrombosis Update
M1 - 100001
ER -